Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | S100B | P04271 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11698215 | 0.85 | MAPT (0.66) | MAPTALDH1A1TDP1HPGDSMN1; SMN2 | |
| SCHEMBL6865515 | 0.84 | MAPT (0.48) | MAPTALDH1A1TDP1HPGDSMN1; SMN2 | |
| SCHEMBL21544269 | 0.83 | ALDH1A1 (0.44) | MAPTALDH1A1HPGDSMN1; SMN2MAPK1 | |
| SCHEMBL12051807 | 0.82 | SMN1; SMN2 (0.52) | MAPTALDH1A1TDP1HPGDSMN1; SMN2 | |
| SCHEMBL29447970 | 0.81 | PDK2 (0.47) | MAPTALDH1A1HPGDSMN1; SMN2CYP3A4 | |
| SCHEMBL1853218 | 0.81 | ALDH1A1 (0.46) | MAPTALDH1A1HPGDSMN1; SMN2CYP3A4 | |
| SCHEMBL13205433 | 0.81 | PDK2 (0.47) | MAPTALDH1A1HPGDSMN1; SMN2CYP3A4 | |
| SCHEMBL849656 | 0.81 | HPGD (0.49) | ALDH1A1HPGDSMN1; SMN2PDK2NPC1 | |
| SCHEMBL11699200 | 0.80 | HPGD (0.66) | MAPTALDH1A1TDP1HPGDSMN1; SMN2 | |
| SCHEMBL436565 | 0.79 | LMNA (0.56) | MAPTALDH1A1TDP1SMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426246-B1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RES INST (TW) | 2024-05-01 | — | — | EP | disclosed |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALITY S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| EP-3880658-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| WO-2020102574-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-10544113-B2 | Thiazolidinone compounds and use thereof | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2020-01-28 | — | — | US | disclosed |
| US-10544113-B2 | Thiazolidinone compounds and use thereof | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2020-01-28 | — | — | US | disclosed |
| EP-3426246-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | National Health Research Institutes (TW) | 2019-01-16 | — | — | EP | disclosed |
| US-20110021519-A1 | TETRAHYDROPTERIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-27 | — | — | US | disclosed |
| US-7763629-B2 | Tetrahydropteridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763629-B2 | Tetrahydropteridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763629-B2 | Tetrahydropteridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-27 | — | — | US | disclosed |
| US-20090062292-A1 | Tetrahydropteridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-03-05 | — | — | US | disclosed |
| US-20090062292-A1 | Tetrahydropteridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-03-05 | — | — | US | disclosed |
| US-20090062292-A1 | Tetrahydropteridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-03-05 | — | — | US | disclosed |
| WO-2008115369-A2 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2007120752-A2 | 4, 5-DIHYDRO- [1, 2, 4] TRIAZOLO [4, 3-F] PTERIDINES AS PROTEIN KINASE PLK1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-25 | — | — | WO | disclosed |
| US-4031073-A | Monoazo pigments containing barbituric acid or thio- or imino-derivatives thereof | CIBA-GEIGY CORPORATION (US) | 1977-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544113-B2 | Thiazolidinone compounds and use thereof | OPRL1, OPRD1, OPRK1 | MAPT 1648/4885ALDH1A1 295/4885TDP1 3865/4885 |
| US-20090062292-A1 | Tetrahydropteridines useful as inhibitors of protein kinases | PRKCH, DMPK, MAP3K20 | MAPT 839/4885ALDH1A1 4527/4885TDP1 885/4885 |
| US-20110021519-A1 | TETRAHYDROPTERIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | PRKCH, DMPK, MAP3K20 | MAPT 839/4885ALDH1A1 4527/4885TDP1 885/4885 |
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MAPT 2169/4885ALDH1A1 2123/4885TDP1 1580/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | MAPT 438/4885ALDH1A1 4184/4885TDP1 1914/4885 |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP3K4, MAP4K2 | MAPT 119/4885ALDH1A1 2196/4885TDP1 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.